“It’s About Our Community”: Newly Formed Science Initiative Aims to Center the Black Experience in HIV and COVID Care
Raniyah Copeland and Stephaun Wallace explain the mission and context for the Black AIDS Institute’s new Scientific Advisory Committee.
“ARCA started because there was a heartbreaking need for new drugs to treat HIV,” says Melanie Thompson, M.D. “The landscape for HIV research has indeed changed, largely as a result of our successes.”
A new expert consensus statement explores how providers can give birthing parents who are living with HIV the information they need to decide for themselves.
No baseline genotyping. Fewer in-person medical visits and lab tests. No need for refills. Could the future of HCV treatment take place almost entirely remotely?
Tonia Poteat, Ph.D., PA-C, M.P.H., and Marlon M. Bailey, Ph.D., dive into the important takeaways of a major new report on sexual and gender diverse populations in the U.S.
“Telling them now that ‘the government is saying I need to decrease your opioids. ... Sorry you’re going to suffer,’ was just not satisfying to me as a physician,” says Maile Young Karris, M.D.
“The message that needs to be communicated to people in power, and it needs to be communicated loud and frequently, is, ‘Look. Here’s the actual human cost of not enacting these kinds of policies. Here’s the potential benefit,’” says Aaron Richterman, M.D., M.P.H.
We spoke with Amy Killelea at NASTAD, a major national health policy advocacy organization, about the priorities she sees in January 2021 and beyond.
IDWeek 2020 provided a perfect opportunity to better understand the modern-day impact of histoplasmosis among Americans living with HIV—and to bone up on the basics.
The process of choosing between PrEP options is often not straightforward. Oni Blackstock, M.D., explains how providers can help ensure their patients end up with the most successful option for them.